RPC
ALXN

Rossmore Private Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Rossmore Private Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9
Closed -$1.08K – 431
2017
Q4 		$1.08K Buy
+9
New +$1.1K ﹤0.01% 434

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rossmore Private Capital's ALXN Position: Q1 2018 in Review

Rossmore Private Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 9 shares — an estimated $1.08K sold.

Rossmore Private Capital first reported a position in ALXN in Q4 2017 and held it in 1 quarter. The position peaked at $1.08K in Q4 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Rossmore Private Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Rossmore Private Capital sold 9 Alexion Pharmaceuticals shares in Q1 2018, an estimated $1.08K.
  • Rossmore Private Capital first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Rossmore Private Capital's Alexion Pharmaceuticals position peaked at $1.08K in Q4 2017.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Rossmore Private Capital's 13F filing for Q1 2018, filed 4 May 2018.